US STOCKS
FUNDS
FX & CRYPTO
SH/SZ-HK
HK STOCKS
 
 
 
 
 
 
To-be Listed (Grey Market Trading Session: 16:15-18:30)
Name
/
Code
Industry Listing Price Lot Size Entry Fee Phillip Grey Market Futu (HK) Grey Market
REFIRE
02570.HK
Grey Market Today
Electrical Components & Equipment Pending 20 3,333
-
-
Detail Quote
Dmall
02586.HK
Grey Market Today
Application Software 30.210 100 N/A
-
-
Detail Quote
Last update: 2024-12-05 08:30:05
Name
/
Code
Industry Offer Price Lot Size Entry Fee Closing Date
Grey Market Date
Listing Date
Mao Geping
01318.HK
Beauty & Toiletries Products and Services 26.3-29.8 100 3,010 2024/12/05 2024/12/09 2024/12/10
Summary
We are the second largest vaccine company in China in terms of 2021 approved lot release volume (excluding COVID-19 vaccines), accounting for a 7.4% market share following state-owned CNBG (中國醫藥集團中國生物技術股份有限公司), the largest vaccine market player in China accounting for a 35.5% market share. In terms of 2021 sales revenue (excluding COVID-19 vaccines), we accounted for a 2.1% market share in the PRC, whereas CNBG ranked first and accounted for 26.5%. As a major vaccine company in China, we cover the full value chain from research and development to manufacturing and to commercialization. According to CIC, we are the only China-based vaccine player that has all five proven human vaccine platform technologies worldwide, namely bacterial vaccine technologies, viral vaccine technologies, genetically engineered vaccine technologies, combination vaccine technologies and mRNA vaccine technologies, with at least one approved product or one vaccine candidate at CTA or clinical stages under each platform. We are one of the first two human vaccine companies in the PRC that have been granted permission under the Fourteenth Five Year Plan of the PRC to build a P3 Lab. In particular, in response to the current pandemic, we have taken full advantages of our full-spectrum platform technologies and are developing COVID-19 vaccine candidates spanning three technology routes validated by approved vaccines, namely mRNA, inactivated virus and recombinant adenoviral vector.

We strive to access the best industry resources. Through one decade of organic growth and external resource integration, we have become a major player in the Chinese vaccine industry. We acquired Rong’an Bio, AIM Honesty, AIM Kanghuai and AIM Weixin, between 2015 and 2017. After these acquisitions, we upgraded their infrastructure and built a number of new production lines to meet the latest GMP standards, improved manufacturing processes and techniques, formulated and executed production plans which closely follow group marketing strategies and consolidated supply chains. Through our standardized management measures, we successfully set up four market-driven Licensed Manufacturing Facilities. Furthermore, we promote a cross-functional and cross-entity R&D approach within the Group. We have established a dedicated R&D department in each of the four operating subsidiaries, with a specific focus on developing new vaccine varieties based on their respective major products and manufacturing specialties, to synergize R&D and manufacturing. We have also established three vaccine research institutes, namely AIM Explorer, Liverna and AIM Jianchi, of which AIM Explorer offers technological support to dedicated R&D departments in the four subsidiaries. Liverna develops mRNA vaccines leveraging its expertise in mRNA technologies, including our mRNA COVID-19 vaccine candidate; and AIM Jianchi focuses on the research and development of genetically engineered recombinant vaccines. These research institutions collaborate with the Licensed Manufacturing Facilities or with each other from time to time to accelerate our pipeline development. See “—Research and Development.” In addition, although each Manufacturing Facility engages in production activities of different products independently, we have a centralized sales and marketing system to synchronize marketing strategy and activities for products from these Manufacturing Facilities, which enables us to consolidate and integrate quality resources at the Group level instead of dispersing into four operating subsidiaries, and build effective sales channels for and strong CDC recognition of our products.

We currently commercialize eight vaccine products against six disease areas, of which the HBV vaccines and human rabies vaccine are our market-leading key commercialized vaccine products. We have been relying on our HBV and human rabies vaccine products during the Track Record Period, from which we generated 84.2%, 90.2%, 93.0%, 94.3% and 92.0% of our total revenue in 2019, 2020, 2021 and the four months ended April 30, 2021 and 2022, respectively. We expect to continue to generate substantial revenue from these two product types in the near future. We also have 22 vaccine candidates against 13 disease areas, of which five candidates are at clinical stages. Out of these five vaccine candidates, we expect to launch at least four from 2023 to 2025. We also plan to file over 10 CTAs by the end of 2023 to advance multiple CTA-enabling and preclinical candidates to clinical trial stages. Our broad vaccine portfolio of large potential market size is illustrated as below:

‧ Our portfolio of vaccine products and vaccine candidates covers all top 10 vaccine products worldwide by 2021 global sales (totaling US$101.9 billion);

‧ In 2021, we were the largest supplier of HBV vaccines in the globe and in the PRC, possessing a 45.4% market share in China in terms of approved lot release volume. In the PRC, anti-HBV vaccination is mandatory for all newborns within 24 hours of birth. In 2021, approximately 75% of China’s newborns received our recombinant HBV vaccine (Hansenula Polymorpha). In addition, we were the third largest HBV vaccine supplier in the PRC in terms of 2021 sales revenue, accounting for a 24.0% market share;

‧ In 2021, we were the second largest supplier of human rabies vaccines in the globe and in the PRC, possessing 18.1% and 16.2% market shares of China market, respectively, in terms of approved lot release volume and sales revenue; and

‧ We have three candidates against COVID-19 (adopting mRNA, inactivated virus and recombinant adenoviral vector technologies), one EV71-CA16 bivalent vaccine candidate against HFMD, three candidates against pneumococcal disease (PCV13, PCV20 and PPSV23), three DTP-based combination candidates (DTcP, DTaP and DTP-Hib) and a number of others with high market potential, most of which target major vaccine-preventable infectious diseases with large-population base and five are potentially first-in-class in the globe or in the PRC.

Our sales and marketing function is centralized, and is specialized and market-oriented, which enables us to accelerate strategy formulation and execution, achieve high cost-efficiency and gain cross-selling opportunities. As of the Latest Practicable Date, we were one of the only four vaccine market players that sold vaccine products to all 31 provinces, direct-controlled municipalities and autonomous regions in China.

Our total revenue was RMB951.6 million, RMB1,638.0 million and RMB1,570.1 million in 2019, 2020 and 2021, respectively. Our gross profit was RMB732.8 million, RMB1,354.1 million and RMB1,294.7 million in 2019, 2020 and 2021, respectively. Our revenue and gross profit grew rapidly by 72.1% and 84.8% respectively from 2019 to 2020; then slightly decreased by 4.1% and 4.4% respectively in 2021 mainly due to the impact of the recurrence of COVID-19 in certain cities in China since late July 2021 on our sales volume in the second half of 2021. Our profit significantly increased by 234.2% from RMB119.8 million in 2019 to RMB400.4 million in 2020. We incurred a substantial loss of RMB675.9 million in 2021, which was resulted primarily from (i) our share-based compensation expenses totaling RMB952.1 million, including a one-off share-based compensation expense of RMB896.9 million and other share-based compensation expenses of RMB55.2 million for other share awards and options granted to our employees, and (ii) an increase in research and development costs from RMB157.8 million to RMB307.4 million to develop our rich pipeline of 22 vaccine candidates. Due to a slowdown in sales amid COVID-19 outbreaks in China, from the four months ended April 30, 2021 to the same period in 2022, our revenue decreased from RMB464.9 million to RMB275.3 million and our gross profit decreased from RMB384.1 million to RMB220.0 million. We had a profit of RMB57.7 million in the four months ended April 30, 2021 but recorded a loss of RMB95.8 million in the same period in 2022, mainly driven by the drop in revenue and as we rapidly advanced clinical trials of our vaccine candidates, which drove up our research and development costs.



Source: AIM Vaccine (06660) Prospectus (IPO Date : 2022/09/23)
Listing Market MAIN
Industry Biotechnology - Pharmaceuticals
Background H Shares
Major Business Area N/A
Corporate Information
Substantial Shareholders Yan ZHOU (Total share: 35.90%); (H share: 4.99%)
Tibet Yingfeng Industrial Co., Ltd. (Total share: 8.10%); (H share: 10.93%)
Ningbo Free Trade Zone Holding Co., Ltd. (Total share: 4.46%); (H share: 10.98%)
Aijun WANG (Total share: 4.13%); (H share: 5.08%)
Shenyang Xixi Enterprise Management Consulting Co., Ltd. (Total share: 3.30%); (H share: 8.13%)
Tibet Oriental Wisdom Investment Management Co., Ltd. (Total share: 3.30%); (H share: 8.13%)
Zhang Chong & Associates (Total share: 3.30%); (H share: 8.13%)
MeiHua Holdings Group Co., Ltd. (Total share: 2.06%); (H share: 5.08%)
Directors Yan ZHOU (Chairman and Chief Executive Officer and Executive Director)
Wen GUAN (Vice Chairman and Executive President and Executive Director)
Xin ZHOU (Executive Vice Chairman and Executive Director)
Shaojun JIA (Executive President and Chief Operation Officer and Executive Director)
Jie ZHOU (Executive Director)
Aijun WANG (Non-Executive Director)
Jichen ZHAO (Non-Executive Director)
Hui OUYANG (Independent Non-Executive Director)
Jie WEN (Independent Non-Executive Director)
Ker Wei PEI (Independent Non-Executive Director)
Xiaoguang GUO (Independent Non-Executive Director)
Company Secretary Ling LIU
Wing Chi LAM
Principal Bankers China Merchants Bank
China Everbright Bank
Solicitors Sullivan & Cromwell (Hong Kong) LLP
Auditors Ernst & Young
Registered Office 5th Floor, Manulife Place, 348 Kwun Tong Road, Kowloon, Hong Kong
Share Registrars Tricor Investor Services Ltd. [Tel: (852) 2980-1333]
Share Registrars Tel No (852) 2980-1333
Internet Address http://www.aimbio.com
Email Address [email protected]
Tel No
Fax No
 
SITEMAP
Email: [email protected]
AASTOCKS.COM LIMITED (阿斯達克網絡信息有限公司) All rights reserved.
Disclaimer
You expressly agree that the use of this app/website is at your sole risk.

AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd, Nasdaq, Inc., their respective holding companies and/or any subsidiaries of such holding companies, their Sources and/or other third party data provider(s) endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co.Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) make any express or implied offers, representations or warranties (including, without limitation, any warranty or merchantability or fitness for a particular purpose or use) regarding the Information.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) will be liable to any Subscriber or any other party for any interruption, inaccuracy, error, or omission, regardless of cause, in the Information or for any damages (whether direct or indirect, consequential, punitive, or exemplary) resulting from its use by any party.

AASTOCKS.com Limited shall not be liable for any failure or delay in performance of its obligations under this Disclaimer because of circumstances beyond its reasonable control, including but without limitation, acts of God, typhoons, rainstorms, other natural disasters, government restrictions, strikes, wars, virus outbreak, network failures or telecommunications failures.

Morningstar Disclaimer: Copyright © 2020 Morningstar, Inc. All Rights Reserved. The information, data, analyses and opinions ("Information") contained herein: (1) include the proprietary information of Morningstar and Morningstar’s third party licensors; (2) may not be copied or redistributed except as specifically authorised; (3) do not constitute investment advice; (4) are provided solely for informational purposes; and (5) are not warranted to be complete, accurate or timely. Morningstar is not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

The information and contents contained in this app/website are based on the analyses and interpretations of publicly available information obtained from sources believed to be reliable. Such analyses and information have not been independently verified and AASTOCKS.com Limited makes no guarantees to their accuracy, completeness, timeliness or correctness.

The information, financial market data, quotes, charts, statistics, exchange rate, news, research, analysis, buy and sell ratings, Education Center and other information on this app/website should be used as references only at your own discretion. Prior to the execution of a security or any other trade based upon the Information, you are advised to consult independent professional advice to verify pricing information or to obtain more detailed market information. AASTOCKS.com Limited is not soliciting any subscriber or app/website visitor to execute any trade. Any trades executed following the said information, commentaries and/or buy/sell ratings on this app/website are taken at your own risk for your own account.

AASTOCKS.com Limited provides the information and services on an "AS IS" basis. The information and contents on this app/website are subject to change without notice. AASTOCKS.com Limited reserves the right, in its sole discretion but without any obligation, to make improvements to, or correct any error or omissions in any portion of this app/website at any time.

The subscriber or app/website visitor agrees not to reproduce, retransmit, disseminate, distribute, broadcast, publish, circulate, sell or commercially exploit the information and contents on this app/website in any manner without the express written consent of AASTOCKS.com Limited.

Investment involves risk. You may make use of the Education Center of this website for academic reference purposes at your own discretion. AASTOCKS.com Limited cannot and does not give any assurance that the present or future buy/sell commentaries and signals on this app/website will be profitable. AASTOCKS.com Limited cannot guarantee, and the subscriber or app/website visitor should not assume, that the future performance will equal past performance.

AASTOCKS.com Limited may point to other sites that may be of interest to the subscriber or app/website visitor but for which AASTOCKS.com Limited has no responsibility and only provides this as a service to the subscriber or app/website visitor.

AASTOCKS.com Limited does not represent or endorse the accuracy or reliability of any information, advertisements or contents contained on, distributed through, or linked, downloaded or accessed from any of the services on this app/website. AASTOCKS.com Limited cannot and does not guarantee the quality or reliability of any products or information purchased or obtained by you as a result of an advertisement or any other information displayed on this app/website.

AATV is a video platform owned by AASTOCKS.com Limited.

You acknowledge that: (i) AATV is provided for information purposes only and, in particular, is not intended for trading purposes; (ii) AATV does not and none of the information contained in its program constitutes a solicitation, offer, opinion, or recommendation by us to buy or sell any security, or to provide legal, tax, accounting, or investment advice or services whether or not regarding the profitability or suitability of any security or investment; and (iii) AATV is not intended for use by, or distribution to, any person or entity in any jurisdiction or country where such use or distribution would be contrary to law or regulation.

The financial analysis or opinion expressed in the AATV programs is for reference and discussion only, and does not represent AASTOCKS.com Limited. Investors must make their own investment decisions based on their own investment objectives and financial situation. AASTOCKS.com Limited shall not, directly or indirectly, be liable, in any way, to you or any other person for any: (i) inaccuracies or errors in or omissions from AATV including, but not limited to, quotes and financial data; (ii) delays, errors, or interruptions in the transmission or delivery of AATV; or (iii) loss or damage arising therefrom or occasioned thereby, or by any reason of nonperformance.

AASTOCKS.com Limited reserves the right to change this Disclaimer at any time by posting changes online at this app/website. You are responsible for reviewing regularly information posted therein to obtain timely notice of such changes. Your continued use of this app / website after changes are posted constitutes your acceptance of this Agreement as modified by the posted changes.

The disclaimer herein shall be governed by the law of the Hong Kong Special Administrative Region of the People's Republic of China ("Hong Kong") and you agree to submit to the exclusive jurisdiction of the Hong Kong courts.

In the event of any discrepancy between the Chinese and English versions, the English version shall prevail.

Last updated on 6 January 2023.